Compare US Global Jets ETF (JETS) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
US Global Jets ETF vs Merck & Co., Inc. — how do they compare? US Global Jets ETF trades at $30.65, while Merck & Co., Inc. trades at $125.94 (market cap $314.90B). The key difference: Merck & Co., Inc. pays a 2.67% dividend while US Global Jets ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, US Global Jets ETF nearer its low. Which is the better fit depends on your goals.
| JETS | MRK | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $33.34 | $129.52 |
52-Week Low | $23.12 | $77.60 |
Market Cap | — | $314.90B |
Enterprise Value | — | $358.32B |
Dividend Yield | — | 2.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JETS trades at $30.50, showing modest daily gains of 0.13% amid mixed technical signals. The ETF faces headwinds from rising fuel costs with airline fuel expenses jumping 85% year-over-year to $6.7 billion in May 2026 (Reuters, 2026-07-07). Technical analysis shows conflicting signals with overall bullish sentiment but bearish moving averages and oscillators, while RSI levels indicate potential oversold conditions. Recent Middle East tensions have pressured airline stocks, though falling oil prices provide some relief.
The outlook remains cautious as fuel cost volatility and competitive pressures challenge airline profitability. Defense-focused alternatives like XAR and PPA offer lower expense ratios and potentially better risk-adjusted returns. JETS' cyclical nature and concentration in industrials require careful monitoring of fuel price trends and travel demand recovery for sustainable upside.
Merck (MRK) trades at $127.50, down slightly by 0.14% today. The stock exhibits a bullish technical trend with strong moving average signals and is trading near its pivot point of $128. Fundamentally, the company reported solid 2025 results with revenue of $65.01 billion and net income of $18.25 billion, though 2026 net income is projected to decline. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives.
The outlook for Merck is supported by analyst optimism, with a consensus price target of $137.30 and 68% buy ratings. Key opportunities include pipeline expansion through acquisitions and strong profitability metrics. Risks involve projected earnings volatility in 2026, competitive pressures in oncology, and macroeconomic factors affecting pharmaceutical valuations. The stock presents a growth-oriented case with manageable near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About US Global Jets ETF
JETS provides targeted exposure to the global airline industry, including commercial airlines, aircraft manufacturers, and airport operators. It focuses on major U.S. and international carriers like Delta, United, and American Airlines.
Read more on JETS →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
